<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Lymphadenopathy — DGRefHelp Drafts</title>
  <link rel="stylesheet" href="../assets/site.css" />
</head>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">
        <h1><a href="../index.html">DGRefHelp drafts</a> / Lymphadenopathy</h1>
        <div class="sub">Evidence summary (key statements + how they fit together) → DGRefHelp first draft (D&amp;G).</div>
      </div>
      <div class="badges">
        <div class="badge">Mode: quick</div>
        <div class="badge">Last updated: 2026‑02‑12</div>
      </div>
    </div>

    <div class="grid">
      <div class="card">
        <div class="card-hd">
          <div class="tabs" data-tabs>
            <button class="tab" role="tab" data-tab="evidence" aria-selected="true">Evidence</button>
            <button class="tab" role="tab" data-tab="draft" aria-selected="false">DGRefHelp draft</button>
            <button class="tab" role="tab" data-tab="refs" aria-selected="false">References</button>
          </div>
          <div class="copybar">
            <button class="btn" data-copy-target="#draftText">Copy draft</button>
            <button class="btn" data-copy-target="#evidenceText">Copy evidence</button>
          </div>
        </div>

        <div class="card-bd">
          <div class="panel active" role="tabpanel" data-panel="evidence">
            <div id="evidenceText" class="section">
              <h3>Evidence summary (triangulated)</h3>

              <div class="callout ok">
                <strong>Key decision points to build the page around</strong>
                <ul>
                  <li><strong>Unexplained isolated node ≥2 cm</strong> persisting ≥6 weeks (or increasing) → treat as <strong>USC</strong> for assessment/biopsy via local pathway (Scottish SRG 2025).</li>
                  <li><strong>Generalised lymphadenopathy</strong> (or nodes with <strong>B symptoms</strong> / hepatosplenomegaly) → <strong>USC haematology</strong> (Scottish SRG 2025; NICE NG12 aligns).</li>
                  <li><strong>Do not miss “looks unwell” patterns</strong>: sepsis/airway compromise/rapidly progressive swelling, or blood film reported suspicious for acute leukaemia → same‑day/emergency routes (SRG 2025).</li>
                </ul>
              </div>

              <h4>1) Scottish Referral Guidelines for Suspected Cancer (SRG) 2025 — Haematological cancers</h4>
              <ul>
                <li>SRG 2025 is explicit about practical thresholds for adult referral/biopsy and a baseline-test set when lymphoma is a possibility.</li>
                <li><strong>When to consider urgent clinical assessment + FBC</strong>: unexplained pallor, bruising/bleeding/petechiae, fatigue/breathlessness, recurrent infections/fever, drenching night sweats, hepatosplenomegaly, and lymphadenopathy (node <strong>≥2 cm</strong> persisting <strong>≥6 weeks</strong> or increasing, or <strong>generalised</strong>).</li>
                <li><strong>Lymphoma baseline tests to consider</strong> (if unexplained features): FBC, renal function, LFTs, calcium, LDH, serum protein electrophoresis, and HIV serology.</li>
                <li><strong>USC haematology</strong> (examples): generalised lymphadenopathy, especially with systemic upset (e.g. drenching night sweats/unintentional weight loss) and/or hepatosplenomegaly/splenomegaly.</li>
                <li><strong>USC “assessment/biopsy via local pathways”</strong>: <strong>unexplained isolated lymphadenopathy ≥2 cm</strong> persisting ≥6 weeks or increasing.</li>
                <li><strong>Good practice</strong>: safety‑net; repeat baseline tests if persistent concern; consider checking HIV status in non-specific symptom presentations.</li>
              </ul>

              <h4>2) NICE NG12 (Suspected cancer) — haematological cancers</h4>
              <ul>
                <li>NICE NG12 supports suspected-cancer-pathway referral for adults with <strong>unexplained lymphadenopathy</strong> for Hodgkin’s and non‑Hodgkin’s lymphoma (and emphasises associated systemic symptoms).</li>
                <li>NG12 also contains separate referral guidance for <strong>neck lumps/head &amp; neck cancers</strong> — clinically, cervical nodes can sit in either camp (local route decision needed).</li>
              </ul>

              <div class="callout warn">
                <strong>Local agreement needed (drafting-site only)</strong>
                <ul>
                  <li>For <strong>unexplained isolated lymphadenopathy ≥2 cm</strong>: confirm D&amp;G route (USC haematology vs “lump clinic”/general surgery vs ENT for cervical nodes) and whether a <strong>direct‑to‑USS</strong> step exists before biopsy.</li>
                  <li>Confirm whether primary care should order baseline tests routinely (FBC/U&amp;E/LFT/LDH/HIV) <strong>before</strong> USC referral, or whether secondary care prefers to own this.</li>
                  <li>Confirm whether D&amp;G uses a Rapid Cancer Diagnostic Service (RCDS) for persistent non-specific symptoms + lymphadenopathy patterns.</li>
                </ul>
              </div>

              <div class="small">This evidence summary is written for pathway design: it highlights only decision‑changing points and where local policy choices sit.</div>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="draft">

            <div class="callout" style="margin-bottom:12px">
              <strong>Copy/paste HTML for Right Decisions accordion sections</strong>
              <div class="small">Per your preference, these snippets contain section content only (no internal headings). Paste each into the matching accordion section.</div>
              <div style="height:10px"></div>
              <div class="copybar" style="justify-content:flex-start">
                <button class="btn" data-copy-target="#htmlBackground">Copy Background HTML</button>
                <button class="btn" data-copy-target="#htmlAssessment">Copy Assessment HTML</button>
                <button class="btn" data-copy-target="#htmlPCM">Copy Primary care mgmt HTML</button>
                <button class="btn" data-copy-target="#htmlRefer">Copy Who to refer HTML</button>
                <button class="btn" data-copy-target="#htmlNotRefer">Copy Who not to refer HTML</button>
                <button class="btn" data-copy-target="#htmlRefs">Copy References HTML</button>
              </div>

              <details style="margin-top:10px">
                <summary class="small" style="cursor:pointer">Show HTML snippets</summary>

                <h4 style="margin:12px 0 6px">Background (HTML)</h4>
                <pre id="htmlBackground">&lt;ul&gt;
  &lt;li&gt;Lymphadenopathy is common; most is reactive/infective. The key job is to not miss malignancy (especially lymphoma/leukaemia) or serious infection.&lt;/li&gt;
  &lt;li&gt;In adults, &lt;strong&gt;unexplained isolated lymphadenopathy ≥2 cm&lt;/strong&gt; persisting ≥6 weeks (or increasing) should be managed as &lt;strong&gt;urgent suspicion of cancer (USC)&lt;/strong&gt; for assessment/biopsy via local pathway.&lt;/li&gt;
  &lt;li&gt;Generalised lymphadenopathy and/or &lt;strong&gt;B symptoms&lt;/strong&gt; (fever, drenching night sweats, weight loss) increases concern for haematological malignancy.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Assessment (primary care) (HTML)</h4>
                <pre id="htmlAssessment">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;First check: is this an emergency / same day?&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Sepsis features, airway compromise, rapidly progressive swelling, severe systemic unwellness → same-day assessment (local acute route).&lt;/li&gt;
      &lt;li&gt;Blood count/film reported suggestive of acute leukaemia/CML → emergency same-day pathway.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;History:&lt;/strong&gt; duration, growth, pain/tenderness; recent infection (URTI/dental/skin); travel/animal exposure; TB risk; sexual history; drugs (e.g. immunosuppression); autoimmune symptoms.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Systemic “B symptoms”:&lt;/strong&gt; fever, drenching night sweats, unintentional weight loss; also pruritus and fatigue.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Examination:&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Node size (measure), site (esp. supraclavicular), texture (hard/fixed vs rubbery/mobile), overlying skin; local source of infection.&lt;/li&gt;
      &lt;li&gt;Check for &lt;strong&gt;generalised lymphadenopathy&lt;/strong&gt; + hepatosplenomegaly.&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Baseline tests (consider when lymphoma/leukaemia possible):&lt;/strong&gt; FBC (± film), U&amp;amp;E, LFT, calcium, LDH; consider HIV serology (local consent/process).&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Primary care management (HTML)</h4>
                <pre id="htmlPCM">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;If clearly reactive (obvious local infection) and improving:&lt;/strong&gt; treat underlying cause + review.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Safety‑net explicitly:&lt;/strong&gt; document size and site; arrange review if not resolving; advise return sooner if increasing size, new nodes, or systemic symptoms.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Do not “watch and wait”&lt;/strong&gt; if node meets USC criteria (see below) or if generalised nodes/B symptoms/hepatosplenomegaly.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who to refer (HTML)</h4>
                <pre id="htmlRefer">&lt;p&gt;&lt;strong&gt;Emergency / same-day&lt;/strong&gt; (local acute route)&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;Sepsis features, airway compromise, rapidly progressive swelling, severe systemic unwellness.&lt;/li&gt;
  &lt;li&gt;Blood count/film reported suggestive of acute leukaemia/CML.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;USC (suspected cancer pathway)&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Generalised lymphadenopathy&lt;/strong&gt; (multiple regions), particularly with &lt;strong&gt;systemic upset / B symptoms&lt;/strong&gt; and/or hepatosplenomegaly/splenomegaly → USC haematology.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Unexplained isolated lymphadenopathy ≥2 cm&lt;/strong&gt; persisting &lt;strong&gt;≥6 weeks&lt;/strong&gt; or increasing in size → USC for assessment/biopsy via local pathway.&lt;/li&gt;
&lt;/ul&gt;

&lt;p class=&quot;small&quot;&gt;Route placeholders (draft): SCI Gateway → (1) Haematology USC (generalised/B symptoms/hepatosplenomegaly) OR (2) local “lymph node / lump assessment” pathway for isolated nodes needing biopsy.&lt;/p&gt;</pre>

                <h4 style="margin:12px 0 6px">Who not to refer (HTML)</h4>
                <pre id="htmlNotRefer">&lt;ul&gt;
  &lt;li&gt;Small tender nodes with an obvious local infection that are resolving, with no red flags and no systemic features.&lt;/li&gt;
  &lt;li&gt;Isolated lymphocytosis or raised paraprotein &lt;em&gt;without&lt;/em&gt; the additional features required for USC referral (follow local non‑USC guidance).&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">References (HTML)</h4>
                <pre id="htmlRefs">&lt;ol&gt;
  &lt;li&gt;Scottish Government. Scottish Referral Guidelines for Suspected Cancer 2025 — Haematological cancers section (includes lymphadenopathy ≥2 cm persisting ≥6 weeks; generalised lymphadenopathy criteria; suggested baseline tests). https://www.gov.scot/publications/scottish-referral-guidelines-suspected-cancer-2025/pages/4/ (retrieved 2026‑02‑12)&lt;/li&gt;
  &lt;li&gt;NICE NG12: Suspected cancer — recognition and referral (haematological cancers recommendations; adults with unexplained lymphadenopathy). https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer (retrieved 2026‑02‑12)&lt;/li&gt;
&lt;/ol&gt;</pre>
              </details>
            </div>

            <div id="draftText" class="section">
              <h3>Lymphadenopathy</h3>

              <h4>Background</h4>
              <ul>
                <li>Lymphadenopathy is common; most is reactive/infective. The key job is to not miss malignancy (especially lymphoma/leukaemia) or serious infection.</li>
                <li>In adults, <strong>unexplained isolated lymphadenopathy ≥2 cm</strong> persisting ≥6 weeks (or increasing) should be managed as <strong>urgent suspicion of cancer (USC)</strong> for assessment/biopsy via local pathway.</li>
                <li>Generalised lymphadenopathy and/or <strong>B symptoms</strong> (fever, drenching night sweats, weight loss) increases concern for haematological malignancy.</li>
              </ul>

              <h4>Assessment (primary care) — collapsible</h4>
              <ul>
                <li><strong>First check: is this an emergency / same day?</strong>
                  <ul>
                    <li>Sepsis features, airway compromise, rapidly progressive swelling, severe systemic unwellness → same-day assessment (local acute route).</li>
                    <li>Blood count/film reported suggestive of acute leukaemia/CML → emergency same-day pathway.</li>
                  </ul>
                </li>
                <li><strong>History:</strong> duration, growth, pain/tenderness; recent infection (URTI/dental/skin); travel/animal exposure; TB risk; sexual history; drugs (e.g. immunosuppression); autoimmune symptoms.</li>
                <li><strong>Systemic “B symptoms”:</strong> fever, drenching night sweats, unintentional weight loss; also pruritus and fatigue.</li>
                <li><strong>Examination:</strong>
                  <ul>
                    <li>Node size (measure), site (esp. supraclavicular), texture (hard/fixed vs rubbery/mobile), overlying skin; look for a local source of infection.</li>
                    <li>Check for <strong>generalised lymphadenopathy</strong> + hepatosplenomegaly.</li>
                  </ul>
                </li>
                <li><strong>Baseline tests (consider when lymphoma/leukaemia possible):</strong> FBC (± film), U&amp;E, LFT, calcium, LDH; consider HIV serology (local consent/process).</li>
              </ul>

              <h4>Primary care management</h4>
              <ul>
                <li><strong>If clearly reactive</strong> (obvious local infection) and improving: treat underlying cause + review.</li>
                <li><strong>Safety-net explicitly:</strong> document size and site; arrange review if not resolving; advise return sooner if increasing size, new nodes, or systemic symptoms.</li>
                <li><strong>Do not “watch and wait”</strong> if node meets USC criteria (below) or if generalised nodes/B symptoms/hepatosplenomegaly.</li>
              </ul>

              <h4>Who to refer</h4>

              <h4>Emergency / same-day (local acute route)</h4>
              <ul>
                <li>Sepsis features, airway compromise, rapidly progressive swelling, severe systemic unwellness.</li>
                <li>Blood count/film reported suggestive of acute leukaemia/CML.</li>
              </ul>

              <h4>USC (suspected cancer pathway)</h4>
              <ul>
                <li><strong>Generalised lymphadenopathy</strong> (multiple regions), particularly with <strong>systemic upset / B symptoms</strong> and/or hepatosplenomegaly/splenomegaly → USC haematology.</li>
                <li><strong>Unexplained isolated lymphadenopathy ≥2 cm</strong> persisting <strong>≥6 weeks</strong> or increasing in size → USC for assessment/biopsy via local pathway.</li>
              </ul>
              <p class="small">Route placeholders (draft): SCI Gateway → (1) Haematology USC (generalised/B symptoms/hepatosplenomegaly) OR (2) local “lymph node / lump assessment” pathway for isolated nodes needing biopsy.</p>

              <h4>Who not to refer</h4>
              <ul>
                <li>Small tender nodes with an obvious local infection that are resolving, with no red flags and no systemic features.</li>
                <li>Isolated lymphocytosis or raised paraprotein <em>without</em> the additional features required for USC referral (follow local non‑USC guidance).</li>
              </ul>

              <h4>Local agreement needed (drafting-site only)</h4>
              <ul>
                <li><label><input type="checkbox" disabled /> For <strong>unexplained isolated lymphadenopathy ≥2 cm</strong>: confirm D&amp;G route (USC haematology vs “lump clinic”/general surgery vs ENT for cervical nodes) and whether a <strong>direct‑to‑USS</strong> step exists before biopsy.</label></li>
                <li><label><input type="checkbox" disabled /> Confirm whether primary care should order baseline tests routinely (FBC/U&amp;E/LFT/LDH/HIV) <strong>before</strong> USC referral, or whether secondary care prefers to own this.</label></li>
                <li><label><input type="checkbox" disabled /> Confirm whether D&amp;G uses a Rapid Cancer Diagnostic Service (RCDS) for persistent non-specific symptoms + lymphadenopathy patterns.</label></li>
              </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="refs">
            <div class="section">
              <h3>References (retrieved 2026‑02‑12)</h3>
              <ol>
                <li>Scottish Government. Scottish Referral Guidelines for Suspected Cancer 2025 — Haematological cancers section (includes lymphadenopathy ≥2 cm persisting ≥6 weeks; generalised lymphadenopathy criteria; suggested baseline tests). <a href="https://www.gov.scot/publications/scottish-referral-guidelines-suspected-cancer-2025/pages/4/">gov.scot</a></li>
                <li>NICE NG12: Suspected cancer — recognition and referral (haematological cancers recommendations; adults with unexplained lymphadenopathy). <a href="https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer">nice.org.uk</a></li>
              </ol>
            </div>
          </div>

        </div>
      </div>

      <div class="footer">
        <a href="../index.html">← Back to topics</a>
      </div>
    </div>
  </div>

  <script src="../assets/site.js"></script>
</body>
</html>
